July 21, 2024
Company Vitrotest has introduced new monoclonal antibodies designed to specifically detect tumor marker HE4 (human epididymis protein 4), a crucial indicator in ovarian cancer. These antibodies are optimized for immunoenzyme assays, enhancing the accuracy of cancer diagnostics by precisely binding to this marker. This product represents a key advancement in diagnostic tools, enabling more reliable and targeted detection methods for healthcare professionals.